Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled, Multicenter, Proof-of-concept, Phase IIA Study of MP1032 Plus Standard of Care vs Standard of Care in the Treatment of Hospitalized Participants With Moderate to Severe COVID-19
Conditions
Interventions
MP1032
Placebo
Locations
31
United States
Snake River Research PLLC
Idaho Falls, Idaho, United States
Richmond University Medical Center
Staten Island, New York, United States
MHAT Blagoevgrad AD
Blagoevgrad, Bulgaria
MHAT Sv. Ivan Rilski Kozloduy
Kozloduy, Bulgaria
MHAT Dr. Stamen Iliev AD
Montana, Bulgaria
SHATPD Pernik EOOD
Pernik, Bulgaria
Start Date
October 19, 2021
Primary Completion Date
July 28, 2022
Completion Date
September 5, 2022
Last Updated
June 29, 2023
NCT06631287
NCT05101213
NCT04565665
NCT06871293
NCT04978571
NCT06082518
Lead Sponsor
MetrioPharm AG
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions